These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

760 related items for PubMed ID: 28364245

  • 21. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [Abstract] [Full Text] [Related]

  • 22. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
    Maruyama R, Yokota T.
    Methods Mol Biol; 2018 Mar; 1828():79-90. PubMed ID: 30171536
    [Abstract] [Full Text] [Related]

  • 23. [Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].
    Takeda S.
    Rinsho Shinkeigaku; 2009 Nov; 49(11):856-8. PubMed ID: 20030230
    [Abstract] [Full Text] [Related]

  • 24. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD.
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M, Tanganyika-de Winter C, Bosgra S, Aartsma-Rus A.
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides.
    Tone Y, Mamchaoui K, Tsoumpra MK, Hashimoto Y, Terada R, Maruyama R, Gait MJ, Arzumanov AA, McClorey G, Imamura M, Takeda S, Yokota T, Wood MJA, Mouly V, Aoki Y.
    Nucleic Acid Ther; 2021 Apr; 31(2):172-181. PubMed ID: 33567244
    [Abstract] [Full Text] [Related]

  • 29. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
    Negishi Y, Ishii Y, Nirasawa K, Sasaki E, Endo-Takahashi Y, Suzuki R, Maruyama K.
    Methods Mol Biol; 2018 Apr; 1687():185-192. PubMed ID: 29067664
    [Abstract] [Full Text] [Related]

  • 30. Optimizing exon skipping therapies for DMD.
    Yokota T, Duddy W, Partridge T.
    Acta Myol; 2007 Dec; 26(3):179-84. PubMed ID: 18646569
    [Abstract] [Full Text] [Related]

  • 31. In Vivo Evaluation of Exon 51 Skipping in hDMD/Dmd-null Mice.
    Sheri N, Yokota T.
    Methods Mol Biol; 2023 Dec; 2640():327-336. PubMed ID: 36995605
    [Abstract] [Full Text] [Related]

  • 32. Viltolarsen for the treatment of Duchenne muscular dystrophy.
    Roshmi RR, Yokota T.
    Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
    [Abstract] [Full Text] [Related]

  • 33. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
    Malerba A, Thorogood FC, Dickson G, Graham IR.
    Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Systemic Injection of Peptide-PMOs into Humanized DMD Mice and Evaluation by RT-PCR and ELISA.
    Melo D, Maruyama R, Yokota T.
    Methods Mol Biol; 2018 Sep; 1828():263-273. PubMed ID: 30171547
    [Abstract] [Full Text] [Related]

  • 36. A Dystrophin Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping.
    Echigoya Y, Trieu N, Duddy W, Moulton HM, Yin H, Partridge TA, Hoffman EP, Kornegay JN, Rohret FA, Rogers CS, Yokota T.
    Int J Mol Sci; 2021 Dec 02; 22(23):. PubMed ID: 34884867
    [Abstract] [Full Text] [Related]

  • 37. Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice.
    Lu-Nguyen NB, Jarmin SA, Saleh AF, Popplewell L, Gait MJ, Dickson G.
    Mol Ther; 2015 Aug 02; 23(8):1341-1348. PubMed ID: 25959011
    [Abstract] [Full Text] [Related]

  • 38. Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts.
    Lee J, Echigoya Y, Duddy W, Saito T, Aoki Y, Takeda S, Yokota T.
    PLoS One; 2018 Aug 02; 13(5):e0197084. PubMed ID: 29771942
    [Abstract] [Full Text] [Related]

  • 39. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
    Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL, Wood MJ.
    Hum Mol Genet; 2009 Nov 15; 18(22):4405-14. PubMed ID: 19692354
    [Abstract] [Full Text] [Related]

  • 40. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B, Wood MJA, Roberts TC.
    RNA Biol; 2021 Jul 15; 18(7):1048-1062. PubMed ID: 33472516
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.